Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement

Nephrol Dial Transplant. 2015 May;30(5):698-700. doi: 10.1093/ndt/gfv050. Epub 2015 Mar 4.

Abstract

This paper reflects the position of the CKD-MBD workgroup, an official working group of ERA-EDTA and of the ERBP advisory board, the official guideline-producing body of ERA-EDTA, on the topic of the use of calcimimetics in patients with CKD stage 5D, as based on two recent meta-analysis.

Keywords: calcimimetics.

MeSH terms

  • Cinacalcet
  • Clinical Trials as Topic
  • Europe
  • Humans
  • Hyperparathyroidism, Secondary / drug therapy*
  • Meta-Analysis as Topic
  • Naphthalenes / administration & dosage
  • Nephrology / standards*
  • Phosphates / chemistry
  • Renal Insufficiency, Chronic / complications*
  • Renal Insufficiency, Chronic / drug therapy*
  • Societies, Medical
  • Sterols / administration & dosage
  • Treatment Outcome
  • Vitamin D / administration & dosage

Substances

  • Naphthalenes
  • Phosphates
  • Sterols
  • Vitamin D
  • Cinacalcet